key: cord-0824029-g66r3ft2
authors: Kramer, Kevin J.; Johnson, Nicole V.; Shiakolas, Andrea R.; Suryadevara, Naveenchandra; Periasamy, Sivakumar; Raju, Nagarajan; Williams, Jazmean K.; Wrapp, Daniel; Zost, Seth J.; Walker, Lauren M.; Wall, Steven C.; Holt, Clinton M.; Hsieh, Ching-Lin; Sutton, Rachel E.; Paulo, Ariana; Davidson, Edgar; Doranz, Benjamin J.; Crowe, James E.; Bukreyev, Alexander; Carnahan, Robert H.; McLellan, Jason S.; Georgiev, Ivelin S.
title: Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition
date: 2021-09-16
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109784
sha: e5efc67d943d095a09bae90529f45988f1aeaf79
doc_id: 824029
cord_uid: g66r3ft2

The emergence of SARS-CoV-2 lineages that are more transmissible and resistant to currently approved antibody therapies poses a considerable challenge to the clinical treatment of COVID-19. Therefore, the need for ongoing discovery efforts to identify broadly reactive monoclonal antibodies to SARS-CoV-2 is of utmost importance. Here, we report a panel of SARS-CoV-2 antibodies isolated using the LIBRA-seq technology from an individual who recovered from COVID-19. Of these antibodies, 54042-4 shows potent neutralization against authentic SARS-CoV-2 viruses, including variants of concern (VOCs). A cryo-EM structure of 54042-4 in complex with the SARS-CoV-2 spike reveals an epitope composed of residues that are highly conserved in currently circulating SARS-CoV-2 lineages. Further, 54042-4 possesses uncommon genetic and structural characteristics that distinguish it from other potently neutralizing SARS-CoV-2 antibodies. Together, these findings provide motivation for the development of 54042-4 as a lead candidate to counteract current and future SARS-CoV-2 VOCs.

Neutralizing antibodies targeting the RBD have been characterized extensively and identical heavy and light chain germline genes and have a virtually indistinguishable structural 247 mode of antigen recognition (RMSD, computed as above, of 1.7Å). Notably, all of 2-7, CoV1404, and REGN10987 have greater interactions with RBD residues 439-441 compared to 249 54042-4, with buried surface areas of 172, 164, 127, and 60 Å 2 for 2-7, LY-CoV1404, 250 REGN10987, and 54042-4, respectively (Figure 4C) , suggesting 2-7, LY-CoV1404, and 251 REGN10987 may be more prone to viral escape in that region. Indeed, the N439K substitution 252 is present in several independent SARS-CoV-2 lineages and has been found to affect binding 253 and neutralization by REGN10987 (Thomson et al., 2021) . 254

Together, these data suggest that antibody 54042-4 utilizes an uncommon genetic 255 signature and a distinct structural mode of antigen recognition compared to other known SARS-256

CoV-2 antibodies. 257

Next, to identify substitutions capable of disrupting binding to antibody 54042-4, we 259 performed shotgun alanine-scanning mutagenesis of the SARS-CoV-2 RBD (Davidson, 2014) . 260

The only tested substitutions that substantially affected binding in comparison to an RBD 261 antibody control were K444A, V445A, G446A, and P499A ( Figure 5A Gly446, Gln498, and Pro499. However, analysis of currently circulating SARS-CoV-2 isolates 272 from the GISAID database as of May 6, 2021 (Elbe, 2017) revealed that substitutions at these 273 five residue positions are only present at low levels ( Figure 5C) . Further, virtually all of the 274 54042-4 epitope residues (Supplemental Figure 3A ) are highly conserved in circulating SARS-275

CoV-2 lineages ( Figure 5C ). The only exception is residue Asn439, which has a substitution 276 frequency of 2.1% ( Figure 5C) ; however, this residue makes only minimal contacts with 277 antibody 54042-4 (Supplemental Figure 3A) , suggesting that residue Asn439 may not be 278 critical for 54042-4 recognition of the SARS-CoV-2 spike. 279

To investigate the ability of antibody 54042-4 to recognize current SARS-CoV-2 VOCs, we 280 performed ELISAs to test binding of 54042-4 to RBD proteins containing substitutions found in 281 one or more VOCs. These substitutions included K417N found in many isolates in the Beta 282 lineage, as well as E484K (Beta, Gamma), N501Y (Alpha, Beta, Gamma), L452R (Delta, 283 Epsilon) and N439K found in lineages B.1.141 and B.1.258 (Thomson et al., 2021) . Notably, 284 antibody 54042-4 bound to these RBD variants at a similar level compared to the binding to the 285 RBD from the Wuhan-1 isolate ( Figure 5D, Supplemental Figure 4A ). These results are 286 consistent with the structural observations that 54042-4 makes only minimal contacts with 287 residue Asn439, and that none of the other RBD substitutions were at residues in the 54042-4 288 epitope (Supplemental Figure 3A) . Binding of antibody 54042-4 also was not affected in the 289 context of SARS-CoV-2 S ECD proteins that included deletions and substitutions in the S1 290 domain of the Alpha and Beta VOCs ( Figure 5D, Supplemental Figure 4B, C) . Finally, we 291 tested the ability of 54042-4 to neutralize authentic SARS-CoV-2 USA-WA1, Alpha, and Beta, 292

Gamma and Delta SARS-CoV-2 variants. Consistent with the ELISA data, 54042-4 neutralized 293 each virus potently with IC 50 values of 3.2, 5.5, 9.7, 3.7, and 1.5, and IC 80 values of 10, 48, 49, 294 J o u r n a l P r e -p r o o f 11.4, and 3.9 ng/mL, respectively ( Figure 5E ). Together, these data indicate that 54042-4 may 295 be an effective countermeasure against currently circulating SARS-CoV-2 variants. 296 297 DISCUSSION 298 SARS-CoV-2 neutralizing antibody discovery efforts have produced an extensive panel 299 of antibodies that show a wide range of functional effects, and most antibodies discovered to 300 date cluster into several classes based on RBD-binding orientation, ACE2 antagonism, and 301 cross-reactivity to related SARS-like coronaviruses (Greaney et al., 2021b) . Here, we report the 302 identification of 54042-4, an antibody that exhibited potent SARS-CoV-2 neutralization against 303 USA-WA1 as well as the currently circulating Alpha, Beta, Gamma, and Delta VOCs. 304

Interestingly, antibody 54042-4 neutralized virus at comparable IC 50 s to the clinical candidates 305 LY-CoV1404 and REGN10987, despite having ~10-fold lower affinity for the RBD (Hansen et 306 al., 2020; Westendorf et al., 2021) . While the epitope of antibody 54042-4 showed partial 307 overlap with that of several other known RBD-directed antibodies, our findings revealed a 308 distinct mode of SARS-CoV-2 spike recognition, paired with an uncommon genetic signature 309 that distinguishes 54042-4 from other SARS-CoV-2 antibodies. Notably, important differences 310 were observed even for the six antibodies with the highest epitope correlations to 54042-4, with 311 all six of these antibodies exhibiting substantially greater contacts with one or more known 312 residues associated with currently circulating VOCs, as well as with other spike residues 313 ( Figure 4C ). While it is not possible to predict what SARS-CoV-2 variants will emerge in the 314 future, having access to antibodies with differences in epitope interactions is critical to 315 broadening the portfolio of countermeasure candidates, should virus variants emerge that are 316 resistant to current therapies. The discovery of antibody 54042-4 is therefore a promising 317 addition to the limited set of antibodies with a high potential for effectively counteracting current Glutamine. These cells were cultured at 37°C with 8% CO 2 saturation and shaking. 546

FreeStyle293F cells were grown while shaking at 37 C in 8% CO2 and 80% humidity. 547 We utilized and modified our previously described pipeline to use paired-end FASTQ files of 667 oligo libraries as input, process and annotate reads for cell barcode, unique molecular identifier 668 (UMI), and antigen barcode, and generate a cell barcode -antigen barcode UMI count matrix 669 (Setliff et al., 2019) . BCR contigs were processed using Cell Ranger (10X Genomics) using 670

GRCh38 as reference. Antigen barcode libraries were also processed using Cell Ranger (10X 671 Genomics). The overlapping cell barcodes between the two libraries were used as the basis of 672 the subsequent analysis. We removed cell barcodes that had only non-functional heavy chain 673 sequences as well as cells with multiple functional heavy chain sequences and/or multiple 674 functional light chain sequences, reasoning that these may be multiplets. Additionally, we 675 aligned the BCR contigs (filtered_contigs.fasta file output by Cell Ranger, 10X Genomics) to 676 J o u r n a l P r e -p r o o f was parsed using ChangeO (Gupta et al., 2015) and merged with an antigen barcode UMI count 678 matrix. Finally, we determined the LIBRA-seq score for each antigen in the library for every cell 679 as previously described (Setliff et al., 2019) . To assess antibody binding, soluble protein was plated at 2 μg/ml overnight at 4°C. The next 722 day, plates were washed three times with PBS supplemented with 0.05% Tween-20 (PBS-T) 723

and coated with 5% milk powder in PBS-T. Plates were incubated for one hour at room 724 temperature and then washed three times with PBS-T. Primary antibodies were diluted in 1% 725

PHENIX: building new 975 software for automated crystallographic structure determination

IMGT((R)) tools for the 978 nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires

IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS

Early introductions and 983 transmission of SARS-CoV-2 variant B.1.1.7 in the United States

SARS-CoV-2 neutralizing 986 antibody structures inform therapeutic strategies

Potent neutralizing 989 antibodies from COVID-19 patients define multiple targets of vulnerability

Increased transmissibility and 993 global spread of SARS-CoV-2 variants of concern as at

Neutralizing Antibody and Soluble ACE2 Inhibition of a 996

Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Resistance of SARS-CoV-2 variants to neutralization by 1000 monoclonal and serum-derived polyclonal antibodies

A neutralizing human antibody binds to the N-terminal domain of the Spike 1003 protein of SARS-CoV-2

COSMIC2 -A Science gateway for 1005 cryo-electron microscopy

COSMIC2: A Science Gateway for Cryo-Electron Microscopy Structure Determination in 1008 Proceedings of the Practice and Experience in Advanced Research Computing

Sustainability, Success, and Impact 1-5

ISOLDE: a physically realistic environment for model building into low-1011 resolution electron-density maps

A high-throughput shotgun mutagenesis approach to mapping B-1013 cell antibody epitopes

The antigenic anatomy of SARS-CoV-2 1016 receptor binding domain

Genetic and structural basis for recognition of 1019

SARS-CoV-2 spike protein by a two-antibody cocktail

SAbPred: a structure-based antibody prediction server

Data, disease and diplomacy: GISAID's innovative contribution to 1024 global health

Coot: model-building tools for molecular graphics

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding 1029 domain that affect recognition by polyclonal human plasma antibodies

Mapping mutations to the SARS-CoV-2 RBD 1033 that escape binding by different classes of antibodies

Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire 1036 sequencing data

Studies in humanized mice and convalescent humans yield a 1039 SARS-CoV-2 antibody cocktail

Controlling the SARS-CoV-2 spike glycoprotein 1042 conformation

SARS-CoV-2 variants B.1.351 and P.1 1045 escape from neutralizing antibodies

Structure-based design of prefusion-stabilized 1048

SARS-CoV-2 spikes

The neutralizing 1051 antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates

Shemer-1054

SARS-CoV-2 spike variants exhibit differential 1055 infectivity and neutralization resistance to convalescent or post-vaccination sera

Structure, Function, and Evolution of Coronavirus Spike Proteins

Potent neutralizing antibodies against multiple epitopes on SARS-1061

CoV-2 spike

SARS-CoV-2 immune evasion by the 1064

.427/B.1.429 variant of concern

SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to 1067 neutralising antibodies and vaccine breakthrough. bioRxiv

Convergent Antibody Responses to SARS-CoV-2

UCSF ChimeraX: Structure visualization for researchers, educators, 1073 and developers

Mapping Neutralizing and 1076

Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-1077

Cross-neutralization of SARS-CoV-2 by a human 1080 monoclonal SARS-CoV antibody

cryoSPARC: algorithms for 1082 rapid unsupervised cryo-EM structure determination

Non-uniform refinement: adaptive regularization 1084 improves single-particle cryo-EM reconstruction

CoV-AbDab: the 1086 coronavirus antibody database

Isolation of potent SARS-CoV-2 neutralizing antibodies and 1089 protection from disease in a small animal model

Alignment of cryo-EM movies of individual particles 1091 by optimization of image translations

Resurgence 1094 of COVID-19 in Manaus, Brazil, despite high seroprevalence

DeepEMhancer: a deep learning solution for cryo-EM volume post-processing

High-Throughput Mapping of B Cell 1099

Structural basis of receptor recognition by SARS-CoV-2

Cross-reactive coronavirus antibodies 1104 with diverse epitope specificities and Fc effector functions

Deep Mutational Scanning of SARS-CoV-1107

Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Neutralizing and protective human 1111 monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Detection of a SARS-CoV-2 variant of concern 1115 in South Africa

Circulating SARS-CoV-2 spike 1118 N439K variants maintain fitness while evading antibody-mediated immunity

Broad sarbecovirus neutralization by a human 1122 monoclonal antibody

Novavax vaccine delivers 89% efficacy against COVID-19 in U.K.-but is 1126 less potent in South Africa

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Broad sarbecovirus neutralizing antibodies 1132 define a key site of vulnerability on the SARS-CoV-2 spike protein

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients 1135 with Covid-19

LY-CoV1404 potently neutralizes SARS-CoV-1138 2 variants

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and 1144 N501Y variants by BNT162b2 vaccine-elicited sera

Structural basis of a shared antibody response to SARS-CoV-2

1149 (2020b). A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 1150 and SARS-CoV

Rapid isolation and profiling of a diverse panel 1153 of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

SARS-CoV-2 Gamma (P.1) SARS-CoV-2 Delta (B.1.617.2)

milk in PBS-T, starting at 10 μg/ml with a serial 1:5 dilution and then added to the plate. The 726 plates were incubated at room temperature for one hour and then washed three times in PBS-T. 727The secondary antibody, goat anti-human IgG conjugated to peroxidase, was added at 1:10,000 728 dilution in 1% milk in PBS-T to the plates, which were incubated for one hour at room 729 temperature. Plates were washed three times with PBS-T and then developed by adding 730 3,3′,5,5′-tetramethylbenzidine (TMB) substrate to each well. The plates were incubated at room 731 temperature for ten minutes, and then 1N sulfuric acid was added to stop the reaction. Plates 732 were read at 450 nm. The area under the curve (AUC) was calculated using GraphPad Prism 733 9.0.1. 734 735 Competition ELISA 736Competition ELISA was performed as done previously (Zost et al., 2020) . Briefly, antibodies 737 were biotinylated using NHS-PEG4-biotin (Thermo Fisher Scientific, cat# A39259) according to 738 manufacturer protocol. Following biotinylation, specific binding of biotinylated antibodies was 739 confirmed using ELISA. Wells of 384-well microtiter plates were coated with 1 µg/mL SARS-740CoV-2 S HP protein at 4ºC overnight. Plates were washed with PBS-T and blocked for 1 h with 741 blocking buffer (1% BSA in PBS-T). Plates were then washed with PBS-T and unlabeled 742 antibodies were added at a concentration of 10 µg/mL in a total volume of 25 µL blocking buffer 743 and incubated 1 h. Without washing, biotinylated antibodies diluted in blocking buffer were 744 added directly to each well in a volume of 5 µL per well (such that the final concentrations of 745 each biotinylated antibody were equal to the respective EC 90 of each antibody), and then 746 incubated for 30 min at ambient temperature. Plates were then washed with PBS-T and 747 incubated for 1 h with HRP-conjugated avidin (Sigma, 25 µL of a 1:3,500 dilution in blocking 748 buffer). Plates were washed with PBS-T and 25 µL TMB substrate was added to each well. After 749 sufficient development, the reactions were quenched by addition 25 µL 1M HCl and absorbance 750 J o u r n a l P r e -p r o o f at 450 nm was quantified using a plate reader. After subtracting the background signal, the 751 signal obtained for binding of the biotin-labeled reference antibody in the presence of the 752 unlabeled tested antibody was expressed as a percentage of the binding of the reference 753 antibody in the presence of 10 µg/mL of the anti-dengue antibody DENV 2D22, which served as 754 a no-competition control. Tested antibodies were considered competing if their presence 755 reduced the reference antibody binding by more than 60% and non-competing if the signal was 756 reduced by less than 30%. 757 758

To screen for neutralizing activity in the panel of recombinantly expressed antibodies, we used a 760 high-throughput and quantitative RTCA assay and xCelligence RTCA HT Analyzer (ACEA 761 Biosciences) that assesses kinetic changes in cell physiology, including virus-induced 762 cytopathic effect (CPE). Twenty µl of cell culture medium (DMEM supplemented with 2% FBS) 763 was added to each well of a 384-well E-plate using a ViaFlo384 liquid handler (Integra 764 Biosciences) to obtain background reading. Six thousand (6,000) Vero-furin cells in 20 μl of cell 765 culture medium were seeded per well, and the plate was placed on the analyzer. Sensograms 766 were visualized using RTCA HT software version 1.0.1 (ACEA Biosciences). For a screening 767 neutralization assay, equal amounts of virus were mixed with micro-scale purified antibodies in 768 a total volume of 40 μL using DMEM supplemented with 2% FBS as a diluent and incubated for 769 1 h at 37 °C in 5% CO2. At ∼17-20 h after seeding the cells, the virus-antibody mixtures were (Sigma-Aldrich) in PBS plus calcium and magnesium (PBS++) before incubation with antibodies 817 diluted in PBS++, 10% normal goat serum (Sigma), and 0.1% saponin. Antibody screening 818 concentrations were determined using an independent immunofluorescence titration curve against 819 cells expressing wild-type spike protein to ensure that signals were within the linear range of 820 detection. Antibodies were detected using 3.75 μg/mL of AlexaFluor488-conjugated secondary 821 antibody (Jackson ImmunoResearch Laboratories) in 10% normal goat serum with 0.1% saponin. 822Cells were washed three times with PBS++/0.1% saponin followed by two washes in PBS, and 823 mean cellular fluorescence was detected using a high-throughput Intellicyte iQue flow cytometer 824 (Sartorius). Antibody reactivity against each mutant spike protein clone was calculated relative to 825 J o u r n a l P r e -p r o o f wild-type spike protein reactivity by subtracting the signal from mock-transfected controls and 826 normalizing to the signal from wild-type S-transfected controls. Mutations within clones were 827 identified as critical to antibody binding if they did not support reactivity of the test antibody, but 828 supported reactivity of other SARS-CoV-2 antibodies. This counter-screen strategy facilitates the 829 exclusion of spike mutants that are locally misfolded or have an expression defect. The virus-serum mixture (100 µl) was added to cell monolayer in duplicates and incubated for 1 839 at h 37°C/5% CO2 atmosphere. Later, virus-serum mixture was discarded gently, and cell 840 monolayer was overlaid with 0.6% methylcellulose and incubated for 2 days. The overlay was 841 removed, and the plates were fixed in 4% paraformaldehyde twice following BSL-3 protocol. 842The plates were stained with 1% crystal violet and virus-induced plaques were counted. The Additional details about data collection parameters can be found in Supplemental Table 1 . 908 909

Motion correction, CTF estimation, particle picking, and preliminary 2D classification were 911 performed using cryoSPARC v3.2.0 live processing (Punjani et al., 2017) . The final iteration of 912 2D class averaging distributed 374,669 particles into 60 classes using an uncertainty factor of 2. 913From that, 241,732 particles were used to perform an ab initio reconstruction with four classes 914 followed by heterogeneous refinement of those four classes. Particles from the two highest 915 quality classes were used for homogenous refinement of the best volume with applied C3 916 symmetry. Non-uniform refinement was performed on the resulting volume using per-particle 917 defocus and per-group CTF optimizations applied (Punjani et al., 2020; Rubinstein and 918 Brubaker, 2015) . To improve the 54042-4 Fab-RBD density, C3 symmetry expansion was 919 performed followed by local refinement using a mask created in ChimeraX that encompassed 920 the entire 54042-4 Fab and RBD (Pettersen et al., 2021) . Local refinement was performed using 921 a pose/shift gaussian prior during alignment, 3° standard deviation of prior over rotation and 1 Å 922 J o u r n a l P r e -p r o o f standard deviation of prior over shifts. Additionally, maximum alignment resolution was limited to 923 2.8 Å resolution to avoid over-refining. To improve map quality, the focused refinement volumes 924 were processed using the DeepEMhancer(Sanchez-Garcia, 2021) tool via COSMIC 2 science 925 gateway, which included the use of our refinement mask to help define noise while sharpening 926 (Cianfrocco, 2017a; Cianfrocco, 2017b ). An initial model was generated Kramer et al. demonstrate that antibody 54042-4 recognizes residues highly conserved across global SARS-CoV-2 isolates. Antibody 54042-4 potently neutralizes all known circulating variants of concern (VOCs), and could be developed as a clinical candidate to treat COVID-19 infection.J o u r n a l P r e -p r o o f